Brief: Tiumbio And Hansoh Pharma Announce Clinical Trial Approval Of 'HS-10518/TU2670' From NMPA In China
05/07/2023 13:15
July 5 (Reuters) - TiumBio Co Ltd 321550.KQ :
* TIUMBIO AND HANSOH PHARMA ANNOUNCE CLINICAL TRIAL APPROVAL
OF
'HS-10518/TU2670' FROM NMPA IN CHINA
* TIUMBIO CO LTD - TIUMBIO WILL COMPLETE LAST PATIENT DOSING
IN A
PHASE 2A CLINICAL TRIAL OF TU2670 IN ENDOMETRIOSIS IN EUROPE BY
END OF YEAR
Source text for Eikon: ID:nPnbG69T0a
Further company coverage: 321550.KQ
((reuters.briefs@thomsonreuters.com;))
Recent news on TiumBio Co
See all newsBrief: TiumBio And Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial Of 'Merigolix For Uterine Fibroids
Brief: TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab
Brief: TiumBio Submits CTA For Phase 1b Clinical Trial Of TU7710
Brief: Tiumbio To Initiate Phase 2 Trial Of Tu2218 For Cancer
Brief: Tiumbio And Hansoh Pharma Announce Clinical Trial Approval Of 'HS-10518/TU2670' From NMPA In China